FDA
-
-
-
-
-
-
-
Virios Therapeutics (VIRI) Reaches Alignment with FDA on Requirements for Advancing IMC-2 for Long-COVID
-
-
-
-
-
-
-
Virios Therapeutics CEO Greg Duncan to Present at the SHARE™️ Series Investor Event on Monday, September 18, 2023
-
-
-
-
-
-
-
Virios Therapeutics Announces Positive Data Demonstrating Improvement in Multiple Long-COVID Symptoms Following Treatment with a Combination of Valacyclovir and Celecoxib in an Exploratory, Open-Labe
-
-
-
-
-
-
-
Virios Therapeutics Announces Fourth Quarter and Full Year 2022 Financial Results
-
-
-
-
-
-
-
Virios Therapeutics Announces Third Quarter 2022 Financial Results and Provides Corporate Update
-
-
-
-
-
-
-
Virios Therapeutics’ Announces Dosing of First Patient in IMC-2 Long-COVID Treatment Trial
-
-
-
-
-
-
-
Virios Therapeutics (VIRI) Expects Fibromyalgia Phase 2b Results in September 2022
-
251,767 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All